Apios americana Medik Extract Alleviates Lung Inflammation in Influenza Virus H1N1- and Endotoxin-Induced Acute Lung Injury.
Apios americana Medik (hereinafter Apios) has been reported to treat diseases, including cancer, hypertension, obesity, and diabetes. The therapeutic effect of Apios is likely to be associated with its anti-inflammatory activity. This study was conducted to evaluate the protective effects of Apios in animal models of acute lung injury induced by lipopolysaccharide (LPS) or pandemic H1N1 2009 influenza A virus (H1N1). Mice were exposed to LPS or H1N1 for 2-4 days to induce acute lung injury. The treatment groups were administered Apios extracts via oral injection for 8 weeks before LPS treatment or H1N1 infection. To investigate the effects of Apios, we assessed the mice for in vivo effects of Apios on immune cell infiltration and the level of pro-inflammatory cytokines in the bronchoalveolar lavage (BAL) fluid, and histopathological changes in the lung. After induction of acute lung injury, the numbers of neutrophils and total cells were lower in the Apios-treated groups than in the non-Apios-treated LPS and H1N1 groups. The Apios groups tended to have lower levels of tumor necrosis factor-a and interleukin-6 in BAL fluid. In addition, the histopathological changes in the lungs were markedly reduced in the Apios-treated groups. These data suggest that Apios treatment reduces LPS- and H1N1-induced lung inflammation. These protective effects of Apios suggest that it may have therapeutic potential in acute lung injury.
Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Sung-Hwa
SH
Sohn
Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Sang-Yeon
SY
Lee
Department of Molecular Medicine, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 406-840, Republic of Korea.
Jun
J
Cui
Department of Molecular Medicine, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 406-840, Republic of Korea.
Ho Hee
HH
Jang
Health Care Institute, Phytomecca Co., Ltd, Incheon 406-840, Republic of Korea.
Tae-Hoon
TH
Kang
Sungkyun Biotech Co., Ltd R&D Center, Sungkyunkwan University, Suwon 440-746, Republic of Korea.
Jong-Keun
JK
Kim
In-Kyoung
IK
Kim
Division of Respiratory, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 137-701, Republic of Korea.
Deuk-Ki
DK
Lee
Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Seulgi
S
Choi
Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Il-Sub
IS
Yoon
Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Ji-Woo
JW
Chung
Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Jae-Hwan
JH
Nam
D055371:Acute Lung Injury / Q000188:drug therapy* / Q000473:pathology; D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000302:isolation & purification / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D016207:Cytokines / Q000032:analysis; D004195:Disease Models, Animal; D004731:Endotoxins / Q000633:toxicity*; D007887:Fabaceae / Q000737:chemistry*; D006651:Histocytochemistry; D053118:Influenza A Virus, H1N1 Subtype / Q000472:pathogenicity*; D007962:Leukocytes / Q000276:immunology; D008168:Lung / Q000473:pathology; D051379:Mice; D010936:Plant Extracts / Q000302:isolation & purification / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D016207:Cytokines; D004731:Endotoxins; D010936:Plant Extracts
Apios; acute lung injury; inflammation; influenza virus; lipopolysaccharide